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Cancer stem cells display an epithelial-mesenchymal transition phenotype and are resistant to current
therapies. In this issue of Cancer Cell, Dong and colleagues demonstrate that these phenotypes in basal-
like breast cancer are promoted by ametabolic switch to glucosemetabolism, resulting in decreased reactive
oxygen species levels.Cancer initiating cells, also referred to
as cancer stem cells (CSCs), exhibit
stem cell-like properties and have been
implicated in the tumorigenesis of basal-
like breast cancer (BLBC), a particularly
aggressive, metastatic and chemo-
therapy-resistant type of breast cancer.
In this issue of Cancer Cell, Dong et al.
(2013) report a metabolic switch to glycol-
ysis following epigenetic silencing of
the gluconeogenic enzyme fructose-1,6-
biphosphatase (FPB1) by the epithelial-
mesenchymal transition (EMT) associated
factor Snail is required for the develop-
ment of BLBC.
CSCs display EMT characteristics such
as loss of the adhesion protein E-cadherin
(Mani et al., 2008). A number of transcrip-
tion factors, including Snail, induce EMT
(Kalluri and Weinberg, 2009). Previously,
the same group reported that Snail inter-
acts with G9a, a methyltransferase
responsible for H3K9me2, and recruits
DNA methyltransferases (DNMTs) to the
E-cadherin promoter. This results in
epigenetic silencing of E-cadherin ex-
pression and promotes primary tumor
growth and metastasis of BLBC cells
(Dong et al., 2012).
To investigate other genes regulated by
the Snail-G9a-Dnmt1 complex in BLBC
cells, Dong et al. (2013) performed a
gene expression mircroarray analysis
following G9a knockdown in a BLBC cell
line and observed a substantial increase
in FBP1 mRNA. Snail-G9a-Dnmt1 was
then shown to directly bind and methylate
the FBP1 promoter, resulting in the epige-
netic silencing of FBP1. Moreover, a
number of other BLBC cell lines had negli-
gible FBP1 expression in contrast to a setof luminal breast cancer cell lines, which
displayed high FBP1 levels. To test if
FBP1 silencing was required for the EMT
characteristics of BLBC cells, Dong et al.
(2013) ectopically expressed Snail alone
or together with FBP1 in ER+-luminal
breast cancer cells. Ectopic expression
of Snail was sufficient to convert these
cells to a BLBC phenotype, as expected.
Importantly, however, Snail expression-
induced EMT and basal-like phenotype
was blocked when FBP1 was coex-
pressed under the control of a promoter
that was not repressed by Snail. More-
over, ectopic expression of FBP1 in
BLBC cells diminished tumor growth in
mice. By contrast, loss of FBP1 in luminal
breast cancer cells increased tumor
growth in mice. This biological observa-
tion appears to be clinically relevant,
because a retrospective analysis of
patients with BLBC revealed that low
FBP1 expression correlated with poor
survival. The loss of FBP1 has also been
previously associated with liver and
gastrointestinal cancers (Chen et al.,
2011). Collectively, these results suggest
that epigenetic silencing of FBP1 is a crit-
ical event in tumorigenesis of BLBC.
The provocative implication of the
current study is that metabolism is not
simply a consequence but rather plays
a causal role in dictating different
phenotypic states exhibited by cancer
cells. But how does an enzyme involved
in glucose metabolism regulate EMT-
like characteristics of BLBC? Glucose
levels are maintained by two reciprocal
metabolic pathways: glycolysis and
gluconeogenesis. Glycolysis is an ATP-
and NADH-generating reaction thatCancer Cell 2results in the catabolism of glucose into
two molecules of pyruvate. Under aerobic
conditions, pyruvate andNADH produced
by glycolysis are then imported into
the mitochondria and flux through the
tricarboxylic acid cycle to generate ATP
through oxidative phosphorylation. Under
low oxygen conditions, pyruvate can
be converted to lactate, regenerating
NAD+ required for glycolysis. Conversely,
gluconeogenesis produces glucose from
pyruvate. Most of the enzymes in glycol-
ysis are reversible and thus can be utilized
for gluconeogenesis. However, there are
three irreversible glycolytic enzymes
including phosphofructose kinase 1
(PFK-1), which converts fructose 6-phos-
phate to fructose 1,6 bisphosphate
(Figure 1). To circumvent PFK-1 during
gluconeogenesis, FBP1 catalyzes the
energy-consuming reaction of converting
fructose 1,6-bisphosphate to fructose 6-
phosphate.
Many human cancer cells display high
flux through glycolysis and other meta-
bolic pathways originating from glycolytic
intermediates. These subsidiary meta-
bolic pathways are involved in the
synthesis of essential amino acids, nucle-
otides (via pentose phosphate shunt), and
lipids. Therefore, an increase in glycolytic
flux may be highly adaptive for prolifera-
tive cells with high demand for cellular
macromolecules (Lunt and Vander
Heiden, 2011). Indeed, Dong et al. (2013)
observed that ectopic expression of
FBP1 in BLBC cell lines decreased
glucose uptake and diminished flux
through both glycolysis and the biosyn-
thetic subsidiary metabolic pathways.
This resulted in an increase in oxygen3, March 18, 2013 ª2013 Elsevier Inc. 265
Figure 1. Epigenetic Silencing of FBP1 Decreases ROS to Promote CSC and EMT Phenotype
in BLBC
FBP1 coverts F-1,6,-BP to F-6P in the rate-limiting step of gluconeogenesis (right). Epigenetic silencing of
FBP1, through promoter methylation by the Snail-G9a-Dnmt1 complex, promotes glycolytic flux. An
increased reliance on glucose metabolism following FBP1 silencing lowers ROS levels by two mecha-
nisms: decreased mitochondrial respiration and increased NADPH synthesis through pentose phosphate
metabolism. Lower ROS levels promote EMT and CSC phenotype in BLBC.
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BLBC utilizes FBP1 silencing as a mecha-
nism to maintain glucose flux through
glycolysis and other associated biosyn-
thetic metabolic pathways.
One emerging idea on how changes in
glucose metabolism induce EMT-like
phenotype is that mitochondrial derived
reactive oxygen species (ROS) could
serve as signaling molecules (Sena and
Chandel, 2012). The mitochondrial
electron transport chain leaks electrons
from complex I, II, and III to molecular
oxygen (O2) to generate superoxide
(O2
), which is rapidly converted to
hydrogen peroxide (H2O2) to activate
cellular signaling. However, higher levels
of ROS can induce cell damage and
death. Indeed, higher FBP1 expression
in BLBC cell lines resulted in increased
mitochondrial ROS. This increase in ROS
levels due to FBP1 expression was critical
for tumor suppression, which could be
prevented by administration of the antiox-
idant N-acetylcysteine. The increased
generation of H2O2 is likely due to
enhanced mitochondrial oxygen con-
sumption as well as the diminished flux
through the pentose phosphate pathway,266 Cancer Cell 23, March 18, 2013 ª2013 Ewhich generates the NADPH required for
enzymes that detoxify H2O2 (Figure 1).
Thus, the low ROS levels in BLBC due to
epigenetic silencing of FBP1 allows for
tumor growth of BLBC cells.
An important consequence of having
low ROS levels is the maintenance of
a subpopulation of CSCs within breast
tumors. These CSCs are relatively insen-
sitive to radiation and chemotherapy
compared to differentiated and pro-
liferative cancer cell populations (Diehn
et al., 2009). Dong et al. (2013) show that
when FPB1 is overexpressed in BLBC
cell lines, the corresponding increase in
ROS levels is accompanied by a signifi-
cantly reduced number of CD44high/
CD24low/EpCAM+ CSC and, as a func-
tional assay, decreased tumorsphere
formation in soft agar. Because CD44
is a direct target of the b-catenin depen-
dent transcriptional machinery, the inves-
tigators hypothesized that increased
ROS, produced through FBP1 overex-
pression, decreased CSC by inhibiting
b-catenin activation. b-catenin acts as co-
activator of the transcription factor TCF4
to induce genes involved in maintaining
stem-like characteristics. Indeed, FBP1lsevier Inc.overexpression decreased b-catenin
signaling by promoting its dissociation
from TCF4. This interaction was restored
with the antioxidant N-acetylcysteine.
Taken together, these data support a
mechanism where epigenetic downregu-
lation of FBP1 increases glycolysis and
decreases ROS, resulting in activation of
b-catenin signaling to maintain CSCs
(Figure 1).
Although Dong et al. (2013) provide
a reasonable explanation for how low
levels of ROS due to FBP1 silencing
maintain CSCs in BLBCs, they do not
mechanistically explore how modulating
FBP1 protein levels can regulate E-cad-
herin protein expression. Presumably,
the Snail-G9a-DNMT complex has
access to the E-cadherin promoter in the
presence or absence of FBP1. Thus, it
was surprising that ectopic expression
of FBP1 was sufficient to block Snail-
dependent epigenetic silencing of E-cad-
herin. Since methylation is a balance
betweenmethyltransferase and demethy-
lase activity, perhaps FBP1 expression
triggers high levels of ROS, which affects
the activity of these enzymes at the
E-cadherin promoter.
A major implication of these findings is
that antioxidants might not be beneficial
in some cancers. A recent study indicated
that non-stem cancer cells can also give
rise to CSCs, indicating the bidirection-
ality between these two populations
(Chaffer et al., 2011). If low levels of ROS
maintain characteristics of CSC, which
are notoriously resistant to radiation and
chemotherapy, then antioxidants would
possibly promote CSC. Might pharmaco-
logically increasing ROS in BLBC pro-
mote the loss of CSCs and improve
patient survival? As new therapies are
developed for BLBC, it will be of interest
how they affect ROS levels and glu-
cose metabolism. Furthermore, therapies
directed in diminishing glucose metab-
olism might be effective against BLBC.
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NOTCH1,which is frequently mutated in T cell acute lymphoblastic leukemia, has been an elusive therapeutic
target. In this issue of Cancer Cell, Roti and colleagues demonstrate that inhibiting SERCA calcium pumps
preferentially impairs the maturation of the most common class of oncogenic Notch1 mutants, thus uncov-
ering a potential therapeutic avenue.The four mammalian Notch receptors are
large type I membrane proteins, sporting
an extracellular domain with 29–36
epidermal growth factor (EGF) repeats
followed by the conserved Lin12-Notch
repeats (LNR) and a heterodimerization
domain (HD; Figure 1A). The LNR and
HD domains constitute the negative
regulatory region (NRR), which maintains
the ‘‘off’’ state of the receptor in the
absence of ligand. Upon binding of Notch
to ligand presented by a neighboring cell,
the NRR undergoes a conformational
change to expose the S2 site to ADAM
metalloprotease cleavage (Figure 1B).
This is followed by g-secretase-mediated
cleavage at the S3 site within the trans-
membrane domain (TMD), which releases
the Notch intracellular domain (NICD).
NICD translocates to the nucleus,
associates with the DNA-binding protein
RBPjk and the transcriptional coactivator
Mastermind (MAM/MAML) to activate
transcription. Activation is linked to phos-
phorylation of the PEST domain, its
recognition and ubiquitination by the E3
ubiquitin ligase FBW7, and NICD degra-
dation (reviewed in Kopan and Ilagan,
2009).Because the Notch signaling pathway
regulates many fundamental processes
during embryonic development and in
self-renewing adult tissues, both gain-
and loss-of-function mutations in path-
way components lead to developmental
disorders, cancer, and other adult onset
diseases. Best known is the contribution
of ligand-independent, activated forms
of Notch1 to T-ALL, more than half of
which gain activating mutations in the
NRR, PEST, or both (Figure 1A; Weng
et al., 2004). The mutations in the NRR
lead to ligand hypersensitivity and
ligand-independent activation, whereas
the PEST domain mutations increase the
stability of NICD and lead to sustained
signaling activity.
The preponderance of NOTCH1 muta-
tions in T-ALL has fueled the search
for effective anti-Notch1 therapeutics
(Figure 1B; reviewed in Tzoneva and
Ferrando, 2012). Because Notch activa-
tion relies on proteolysis, g-secretase
inhibitors (GSIs), which had been origi-
nally developed for Alzheimer’s disease
therapy, have entered clinical trials for
treatment of relapsing T-ALL. However,
sustained GSI inhibition is not tolerated,because pan-Notch blockade causes
severe gastrointestinal toxicity and
promotes progression of squamous cell
carcinomas (Extance, 2010). The same
problems could affect the efficacy of
stapled dominant negative MAML-like
peptides (SAHM) that directly target the
transcription complex. More recently,
receptor-specific anti-NRR1 antibodies
have been developed. Despite their ability
to circumvent gut toxicity, sustained
treatment with these reagents will likely
cause vascular neoplasms, raising addi-
tional safety concerns (Yan et al., 2010).
To identify modulators of Notch1 sig-
naling and potential therapeutic targets
for T-ALL, Roti et al. (2013; in this issue
of Cancer Cell) conducted complemen-
tary high throughput small molecule
and cDNA overexpression screens using
cell-based assays reporting Notch tran-
scriptional activity. For the compound
screen, the transcriptional signature of
Notch in T-ALL was assembled from
previous genome-wide expression pro-
filing studies of multiple human T-ALL
cell lines treated with vehicle or GSI.
They validated a group of 28 target and
4 nontarget genes to generate a robust,3, March 18, 2013 ª2013 Elsevier Inc. 267
